I
n the late twentieth century, there was a rise in a type of cancer called mesothelioma, which is caused by exposure to asbestos used in building materials. Mesothelioma often arises decades after exposure, accounting for tens of thousands of deaths annually worldwide 1 . Even with the treatments currently available, it is inevitably fatal. There is therefore an urgent need to develop more effective therapies for this type of cancer. Wu et al. 2 report on page 402 that mutations in a cellsignalling pathway that commonly occur in meso thelioma create a tumour vulnerability that might be targeted to treat this disease.
Mesothelioma most often originates in the lining of the lungs, in cells that form the pleural membrane. Mutations frequently found in mesothelioma cells often inactivate proteins, called tumour suppressors, that function in anticancer pathways. One of the most common such inactivated proteins is called merlin (encoded by the NF2 gene), which functions in the highly evolutionarily conserved Hippo signalling pathway. This pathway was originally identified in the fruit fly Drosophila melanogaster 3, 4 , and it comprises a signalling cascade that controls cell proliferation and organ size. If merlin or another protein in this pathway, such as LATS2, is inactivated, downstream proteins called YAP and TAZ can boost the expression of genes that promote tumour formation. Certain cancers can even become 'addicted' to YAP-mediated transcription for their survival 5 . However, if merlin, LATS2 and another protein called LATS1 are functional, YAP and TAZ undergo phosphoryl ation (a phosphate group is attached to them), which modifies the proteins and blocks their function by preventing them from entering the nucleus to drive gene expression 6 . Mutations in the genes encoding merlin and LATS2 are positively selected during tumour development 7 , consistent with their normal roles as tumoursuppressor proteins in mesothelioma.
Wu and colleagues studied the geneexpression profiles of human cancer cells grown in vitro, and report that YAP and TAZ drive the expression of proteins, such as ACSL4, that are needed for a type of cell death called ferro ptosis. The authors also uncovered a connection between the ability of cells to suppress ferro ptosis and the cell-cell contact that depends on the protein E-cadherin. The authors report that high expression of E-cadherin in human mesothelioma cells grown in vitro is associated with resistance to ferro ptosis. E-cadherin activates the Hippo pathway, and the authors went on to explore the relationship between this pathway and ferroptosis.
Cell death that occurs through ferroptosis depends on a reaction between cellular iron and hydrogen peroxide 8 . During ferroptosis, a polyunsaturated fatty acid -a type of lipid found in the cell membrane -undergoes a modification called peroxidation, which causes an increase in the level of molecules termed reactive oxygen species. Ferroptosis is often linked to depletion of the amino acid cysteine, which is imported into cells by the protein SLC7A11. Cysteine provides a building block for the production of glutathione, a molecule involved in a pathway that can combat ferroptosis.
The drug sorafenib is approved for clinical use. It can induce ferroptosis by inhibiting SLC7A11. The authors demonstrate that sorafenib treatment of cultured human mesothelioma cells that have mutations in the gene encoding merlin causes the cells to undergo ferroptosis. They report that this sensitivity to ferroptosis depends on YAP-and TAZ-mediated gene expression (Fig. 1) .
Two independent clinical trials 9,10 found that sorafenib caused tumour shrinkage or stabilization in people with mesothelioma. However, neither trial evaluated the mutations present in the patients' tumours, and it is tempting to speculate that the tumours of people who responded particularly well had mutations that inhibited the Hippo signal ling pathway and that thereby boosted Might other mutations beyond those in the Hippo pathway also regulate ferroptosis in mesothelioma? The most commonly mutated gene in this cancer 11 encodes the tumour-suppressor protein BAP1. This enzyme affects gene expression, and can cause a reduction in the expression of SLC7A11, which, in turn, leads to ferroptosis 12 . If the gene that encodes BAP1 is mutated, ferroptosis does not occur 12 . Therefore, the presence of wildtype BAP1 might help to enhance ferroptosis, along with any boost to ferroptosis provided by the use of SLC7A11 inhibitors. It is not known whether drugs that induce ferroptosis, such as sorafenib, would be effective in cells in which mutations inactivate BAP1.
Other approaches to targeting meso thelioma in which the Hippo pathway is in activated are being explored. For example, in animal studies, loss of merlin expression is associated with cancer-cell vulnerability to inhibition of a protein called focal adhesion kinase 13 . However, no clinical benefit was found with this approach in a clinical trial 14 . Direct targeting of the interaction between YAP and TEAD, a protein to which YAP binds when it drives gene expression, is another strategy being pursued to block cancer-promoting gene expression 15 . Finally, YAP and TAZ recruit the protein BRD4 to drive the expression of specific genes, and use of a small-molecule inhibitor to target BRD4 can disrupt YAP-and TAZ-mediated gene expression 16 . This class of small-molecule inhibitor is entering early clinical trials. All of these approaches aim to block YAP-and TAZmediated gene expression. However, if the anticancer strategy being used aimed to trigger ferroptosis in mesothelioma cells, then YAPand TAZ-mediated gene expression would be required.
Identifying a tumour that has an inactivated Hippo signalling pathway as a means of a developing personalized cancer therapythe ultimate goal -poses some challenges for mesothelioma. Focusing only on tumours that have lost merlin function would probably miss meso theliomas in which Hippo signalling is inhibited by inactivation of other proteins, such as LATS1 and LATS2. A previous study 17 of the Hippo pathway in various cancers has revealed that 22 genes are commonly trans cribed by YAP and TAZ, and this transcriptional profile might offer a way to identify ferroptosis-sensitive tumours. Further more, because this profile was found 17 in several types of tumour, triggering ferroptosis might be worth exploring for cancers other than mesothelioma.
Wu and colleagues' report highlights a strategy that could offer a way of developing a personally tailored anticancer therapy. However, therapies targeted to mutations in an individual's mesothelioma are still in their infancy. Clinical trials that take this approach, for example the mesothelioma stratified therapy trial in which I am involved (see go.nature. com/2o19lah), might help to make progress in such endeavours, and provide improved treatments at a time of unmet clinical need. ■ 
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n the past couple of years, NASA's Juno spacecraft has measured Jupiter's gravitational field with exquisite accuracy 1,2 . The results have revealed that the planet's fluid hydrogen-helium envelope does not have a uniform composition: the inner part contains more heavy elements than the outer part 3, 4 . On page 355, Liu et al. 5 propose that this asym metry resulted from a head-on collision between the young Jupiter and a planetary embryo that had a mass about ten times that of Earth. The authors suggest that the primordial cores of the planet and of the embryo would have merged and then partially mixed with Jupiter's envelope, explaining the structure of the planet seen today.
Scars of impacts abound on rocky planetary bodies. For example, the Moon is covered in craters, and was formed by a collision that occurred 4.5 billion years ago between Earth and a massive body 6 . Although impacts leave no direct imprint on the surfaces of fluid planets, the tilts of the rotational axes of Saturn (27°), Uranus (98°) and Neptune (30°) might indicate that violent collisions occurred in the past 7 . After all, it is known that massive planetary embryos on the order of ten Earth masses must have been present in the early Solar System 8 , in addition to the planets that are still here. Jupiter, with its small tilt (3°), seems to have escaped unscathed 7 . But according to Liu and colleagues, this was not the case.
Jupiter is mostly made of hydrogen and helium. However, observations of its atmospheric composition 9 and gravitational field show that it contains a non-negligible proportion of heavier elements in the form of a central core and in the hydrogen-helium envelope. This envelope is fluid and is expected to be largely convective 10 , so it was surprising when Juno revealed that the envelope's composition is not uniform. Instead, the core seems to be partially diluted in the envelope, extending to almost half of the planet's radius 3, 4 (Fig. 1 ). Producing this internal structure directly would require the delivery (accretion) of 10-20 Earth masses 3, 4 of heavy elements to the young Jupiter after the core had formed and during the first half of the growth of the envelope. The accretion of this material would need to have stopped after the planet had grown to about half of its present mass.
Formation models indicate that this hypothesis is unlikely. In these models, when Jupiter reaches about 30 Earth masses, the growth of the envelope by accretion is fast 11 , and the planet efficiently pushes away any dust particle that is millimetre-sized or larger 12 . As a result, the envelope should be poor in heavy elements. Any subsequent delivery of heavy elements by planetesimals (the asteroid-sized precursors of planets) or small planets is in efficient and cannot explain a heavy-element abundance that would increase with depth, as is observed. Erosion of the core into the envelope is possible 10, 13 , but simulations show that this process tends to remove any small composition gradients that exist in the PLANETARY SCIENCE
Signs that Jupiter was mixed by a giant impact
Simulations suggest that Jupiter's dilute core might be the result of a collision between the planet and a Uranus-mass planetary embryo. This finding indicates that giant impacts could be common during planet formation. See Letter p.355
